Altasciences said its formulation, manufacturing and analytical services facilities in Philadelphia, PA, are undergoing further expansion. The CRO/CDMO is building client-dedicated facilities for Alladapt Immunotherapeutics, a clinical-stage biopharma company developing prescription therapeutics to address IgE-mediated food allergy, with a scheduled completion time in 2023.

Having developed the formulation and manufacturing processes to meet all of Alladapt’s Phase I and II clinical trial needs, Altasciences has been contracted to continue the process with the construction of a new 53,000-square-foot building that will meet Alladapt’s Phase III and commercial requirements. Altasciences will manage all aspects of this project, including warehousing, release management, manufacturing, quality assurance and finished product release. The new building will have additional client dedicated capacity that can be used for Phase I through to commercial manufacturing services.

“We are pleased to continue supporting Alladapt in their important goal of developing a single therapeutic to address a wide range of mono- and multi-food allergies, and we look forward to fulfilling their Phase III and commercial requirements,” said Ben Reed, general manager, CDMO services at Altasciences.

Ashley Dombkowski, co-founder and CEO at Alladapt, said, “The training Altasciences provides their CDMO workforce is second to none, as each team member is well-equipped to optimize and complete our manufacturing projects. We are proud to partner with Altasciences to continue advancing the clinical development of our potentially best in-class oral immunotherapy candidate, ADP101.”